Bristol-Myers Hits Sandoz Over Generic Hepatitis Drug

Law360, New York (June 21, 2012, 7:39 PM EDT) -- Bristol-Myers Squibb Co. on Thursday filed suit in Delaware federal court alleging Sandoz Inc.'s plan to make a generic version of the hepatitis B drug Baraclude would lead to infringement of BMS' patent for the medication.

BMS said in its complaint that unless Sandoz is blocked from carrying through with plans to make entecavir — the active ingredient in Baraclude — which it submitted in an abbreviated new drug application to the U.S. Food and Drug Administration, the generic maker would infringe BMS’s U.S. Patent Number...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.